Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Wall Street Zen

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings lowered shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research note on Thursday, July 9th. Piper Sandler cut their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Finally, Zacks Research cut Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $16.78 on Friday. The stock has a market capitalization of $1.77 billion, a PE ratio of -5.79, a P/E/G ratio of 0.22 and a beta of 0.23. Sarepta Therapeutics has a 1 year low of $14.68 and a 1 year high of $25.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The company’s 50-day simple moving average is $16.92 and its 200-day simple moving average is $18.49.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SRPT. Yousif Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 1.9% during the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock worth $541,000 after purchasing an additional 481 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Sarepta Therapeutics by 7.8% in the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 636 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after purchasing an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Sarepta Therapeutics by 1.8% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock valued at $829,000 after purchasing an additional 758 shares during the last quarter. Finally, Larson Financial Group LLC increased its stake in Sarepta Therapeutics by 82.5% in the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 851 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Options activity turned notably bullish: traders purchased 4,625 call options on Friday, about 47% above the typical daily volume of 3,153 contracts. This suggests increased speculative interest in an upside move, although options activity does not guarantee a sustained rally.
• Positive Sentiment: Sarepta exceeded Wall Street expectations in the second quarter of 2026, reporting earnings of $0.64 per share versus the $0.58 consensus estimate and delivering a revenue beat of approximately 12.85%. The company also reported $13 million in GAAP operating income, highlighting improved profitability. Sarepta Q2 earnings and revenue results
• Positive Sentiment: Management emphasized progress in its siRNA pipeline and a strategic shift under its recently appointed chief executive officer. Pipeline advances could help diversify Sarepta beyond its current commercial products and strengthen the longer-term investment case. Sarepta Q2 earnings call highlights
• Neutral Sentiment: The company’s financial performance improved, but reported earnings were below the $2.02 per-share result from the same quarter last year. Investors may therefore focus on whether the profitability gains are sustainable.
• Negative Sentiment: Elevidys sales were weaker than expected, and Sarepta narrowed its 2026 product-revenue outlook while tightening expense guidance. The lower outlook could offset the positive impact of the quarterly earnings and revenue beats. Sarepta Q2 earnings and 2026 outlook
• Negative Sentiment: RBC highlighted competitive pressures despite Sarepta’s pipeline updates. That raises concerns about Elevidys’ future sales trajectory and the company’s ability to maintain growth in a more competitive rare-disease market. RBC analysis of Sarepta competitive pressures

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.